|
1
|
Russo J and Russo IH: The role of estrogen
in the initiation of breast cancer. J Steroid Biochem Mol Biol.
102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.PubMed/NCBI
|
|
3
|
Graham JD, Yeates C, Balleine RL, et al:
Characterization of progesterone receptor A and B expression in
human breast cancer. Cancer Res. 55:5063–5068. 1995.PubMed/NCBI
|
|
4
|
Sengupta S and Jordan VC: Selective
estrogen modulators as an anticancer tool: mechanisms of efficiency
and resistance. Adv Exp Med Biol. 630:206–219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levin ER and Pietras RJ: Estrogen
receptors outside the nucleus in breast cancer. Breast Cancer Res
Treat. 108:351–361. 2008. View Article : Google Scholar
|
|
7
|
Pietras RJ and Szego CM: Specific binding
sites for oestrogen at the outer surfaces of isolated endometrial
cells. Nature. 265:69–72. 1977. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pedram A, Razandi M and Levin ER: Nature
of functional estrogen receptors at the plasma membrane. Mol
Endocrinol. 20:1996–2009. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toran-Allerand CD, Guan X, MacLusky NJ, et
al: ER-X: a novel, plasma membrane-associated, putative estrogen
receptor that is regulated during development and after ischemic
brain injury. J Neurosci. 22:8391–8401. 2002.PubMed/NCBI
|
|
10
|
Song RX, Fan P, Yue W, Chen Y and Santen
RJ: Role of receptor complexes in the extranuclear actions of
estrogen receptor α in breast cancer. Endocr Relat Cancer. 13(Suppl
1): S3–S13. 2006. View Article : Google Scholar
|
|
11
|
Razandi M, Pedram A, Park ST and Levin ER:
Proximal events in signaling by plasma membrane estrogen receptors.
J Biol Chem. 278:2701–2712. 2003. View Article : Google Scholar
|
|
12
|
Zheng A, Kallio A and Harkonen P:
Tamoxifen-induced rapid death of MCF-7 breast cancer cells is
mediated via extracellularly signal-regulated kinase signaling and
can be abrogated by estrogen. Endocrinology. 148:2764–2777. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Simian M, Manzur T, Rodriguez V, de Kier
Joffe EB and Klein S: A spontaneous estrogen-dependent,
tamoxifen-sensitive mouse mammary tumor: a new model system to
study hormone-responsiveness in immune competent mice. Breast
Cancer Res Treat. 113:1–8. 2009. View Article : Google Scholar
|
|
14
|
Pontiggia O, Rodriguez V, Fabris V, et al:
Establishment of an in vitro estrogen-dependent mouse mammary tumor
model: a new tool to understand estrogen responsiveness and
development of tamoxifen resistance in the context of
stromal-epithelial interactions. Breast Cancer Res Treat.
116:247–255. 2009. View Article : Google Scholar
|
|
15
|
Pontiggia O, Sampayo R, Raffo D, et al:
The tumor microenvironment modulates tamoxifen resistance in breast
cancer: a role for soluble stromal factors and fibronectin through
β1 integrin. Breast Cancer Res Treat. 133:459–471. 2012. View Article : Google Scholar
|
|
16
|
Vallejo G, Ballare C, Baranao JL, Beato M
and Saragueta P: Progestin activation of nongenomic pathways via
cross talk of progesterone receptor with estrogen receptor β
induces proliferation of endometrial stromal cells. Mol Endocrinol.
19:3023–3037. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferlini C, Scambia G, Marone M, et al:
Tamoxifen induces oxidative stress and apoptosis in oestrogen
receptor-negative human cancer cell lines. Br J Cancer. 79:257–263.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gharbi SI, Zvelebil MJ, Shuttleworth SJ,
et al: Exploring the specificity of the PI3K family inhibitor
LY294002. Biochem J. 404:15–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stice JP, Mbai FN, Chen L and Knowlton AA:
Rapid activation of nuclear factor κB by 17β-estradiol and
selective estrogen receptor modulators: pathways mediating cellular
protection. Shock. 38:128–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McDonald GT, Sullivan R, Pare GC and
Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes
tumor cell resistance to chemotherapeutic agents via a mechanism
involving delay in cell cycle progression. Exp Cell Res.
316:3197–3206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grovdal LM, Kim J, Holst MR, Knudsen SL,
Grandal MV and van Deurs B: EGF receptor inhibitors increase ErbB3
mRNA and protein levels in breast cancer cells. Cell Signal.
24:296–301. 2012. View Article : Google Scholar
|
|
22
|
Hirata A, Hosoi F, Miyagawa M, et al: HER2
overexpression increases sensitivity to gefitinib, an epidermal
growth factor receptor tyrosine kinase inhibitor, through
inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Cancer Res. 65:4253–4260. 2005. View Article : Google Scholar : PubMed/NCBI
|
